Fig 1: In normoxia conditions, DRIs are able to improve the activity of CDDP/VP-16 combination against human ovarian cancer cells PEA1 (A,C,E,G,I) and PEA2 (B,D,F,H,J). DRIs significantly increase CDDP/VP-16 induced level of DNA damage (A,B), the level of phosphorylated H2AX (C,D), modulate DNA repair (E,F), affect the distribution of cell cycle (G,H) and caspases 3 and 7 activity (I,J). Results are presented as the mean ± SEM (A,B) or mean ± SD (C–J) of 3 independent experiments, *—p < 0.05; **—p < 0.01; ***—p < 0.001.
Fig 2: In hypoxia conditions, DRIs are unable to improve the activity of CDDP/VP-16 combination against human ovarian cancer cells PEA1 (A,C,E,G,I) and PEA2 (B,D,F,H,J). DRIs did not significantly increase CDDP/VP-16 induced level of DNA damage (A,B), the level of phosphorylated H2AX (C,D), the DNA repair (E,F) and did not affect the distribution of cell cycle (G,H). A significant increase in the caspase 3/7 level was observed for CDDP-resistant PEA2 cells but not for its CDDP-sensitive counterpart (I,J). Results are presented as the mean ± SEM (A,B) or mean ± SD (C–J) of 3 independent experiments, ***—p < 0.001.
Supplier Page from Abcam for Human H2A.X (phospho S139) In-Cell ELISA Kit (IR)